Virax Biolabs to Participate at 7th European Congress of Immunology

Rhea-AI Summary

Virax Biolabs Group (VRAX) has announced its participation in the 7th European Congress of Immunology (ECI) from September 1-4, 2024, in Dublin, Ireland. The company will showcase its immune profiling products for research use at Booth C13. Management will be available for discussions with research organizations and potential customers.

The ECI is a prestigious triennial event organized by the European Federation of Immunological Societies (EFIS), attracting over 3,000 delegates in the field of basic and clinical immunology. This year's congress theme is 'Conquering challenges with Immunology', highlighting the importance of immunological research in addressing current health challenges.

News Market Reaction – VRAX

+3.90%

1 alert

+3.90% News Effect

On the day this news was published, VRAX gained 3.90%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

LONDON, Aug. 29, 2024 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today it will be hosting a booth at the 7^th European Congress of Immunology (ECI), which is taking place from September 1 - 4, 2024, in Dublin, Ireland.

The Company will be showcasing its portfolio of immune profiling products for research use at Booth C13, and management will be available for discussions with research organizations and potential customers.

The European Congress of Immunology is the triennial joint meeting of all European Federation of Immunological Societies (EFIS). It is now one of the most highly regarded international conferences in the field of basic and clinical immunology, attracting on average more than 3,000 delegates and offering the highest standards in terms of both scientific and social programs. The theme for this year's congress is 'Conquering challenges with Immunology'.

About Virax Biolabs Group Limited

Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.

For more information, please visit www.viraxbiolabs.com.

Investor Relations Contact:
Russo Partners, LLC 
Nic Johnson and Adanna G. Alexander, Ph.D. 
M: 303-482-6405 
nic.johnson@russopartnersllc.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-to-participate-at-7th-european-congress-of-immunology-302234080.html

SOURCE Virax Biolabs

FAQ

When and where is Virax Biolabs (VRAX) participating in the European Congress of Immunology?

Virax Biolabs (VRAX) is participating in the 7th European Congress of Immunology from September 1-4, 2024, in Dublin, Ireland.

What products will Virax Biolabs (VRAX) showcase at the 7th European Congress of Immunology?

Virax Biolabs (VRAX) will showcase its portfolio of immune profiling products for research use at Booth C13 during the congress.

How many delegates typically attend the European Congress of Immunology?

The European Congress of Immunology typically attracts more than 3,000 delegates from the field of basic and clinical immunology.

What is the theme of the 7th European Congress of Immunology in 2024?

The theme for the 7th European Congress of Immunology in 2024 is 'Conquering challenges with Immunology'.